A new trading day began on Monday, with Cardiff Oncology Inc (NASDAQ: CRDF) stock price up 16.69% from the previous day of trading, before settling in for the closing price of $3.20. CRDF’s price has ranged from $0.94 to $6.42 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 9.26%. Meanwhile, its annual earnings per share averaged -7.72%. With a float of $42.94 million, this company’s outstanding shares have now reached $44.68 million.
The extent of productivity of a business whose workforce counts for 32 workers is very important to gauge. In terms of profitability, gross margin is 37.29%, operating margin of -6711.28%, and the pretax margin is -6143.91%.
Cardiff Oncology Inc (CRDF) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Cardiff Oncology Inc is 7.76%, while institutional ownership is 25.92%. The most recent insider transaction that took place on Dec 19 ’23, was worth 41,100. In this transaction Director of this company bought 30,000 shares at a rate of $1.37, taking the stock ownership to the 697,761 shares.
Cardiff Oncology Inc (CRDF) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -7.72% per share during the next fiscal year.
Cardiff Oncology Inc (NASDAQ: CRDF) Trading Performance Indicators
Here are Cardiff Oncology Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.97. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 266.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.91, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -1.04 in one year’s time.
Technical Analysis of Cardiff Oncology Inc (CRDF)
The latest stats from [Cardiff Oncology Inc, CRDF] show that its last 5-days average volume of 1.21 million was superior to 0.93 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 75.78%. Additionally, its Average True Range was 0.25.
During the past 100 days, Cardiff Oncology Inc’s (CRDF) raw stochastic average was set at 97.19%, which indicates a significant increase from 95.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.85% in the past 14 days, which was higher than the 72.02% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.63, while its 200-day Moving Average is $3.00. Now, the first resistance to watch is $4.00. This is followed by the second major resistance level at $4.26. The third major resistance level sits at $4.73. If the price goes on to break the first support level at $3.27, it is likely to go to the next support level at $2.80. Assuming the price breaks the second support level, the third support level stands at $2.54.
Cardiff Oncology Inc (NASDAQ: CRDF) Key Stats
With a market capitalization of 178.84 million, the company has a total of 46,550K Shares Outstanding. Currently, annual sales are 490 K while annual income is -41,440 K. The company’s previous quarter sales were 160 K while its latest quarter income was -11,780 K.
